Mezun Olduğu Tıp Fakültesi ve Yılı
Ankara Üniversitesi Tıp Fakültesi (2000)
Uzmanlık Eğitimi Aldığı Yer ve Yılı
Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Tıpta Uzmanlık Eğitimi-2005
Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Gastroenteroloji Bilim Dalı Tıpta Yan Dal Uzmanlık Eğitimi-2008
Mesleki Deneyim
Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı'nda Tıpta Uzmanlık Eğitimi (2000-2005)
Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Gastroenteroloji Bilim Dalı'nda Tıpta Yan Dal Uzmanlık Eğitimi (2005-2008)
Tulane Üniversitesi (New Orleans, ABD) Gastroenteroloji-Hepatoloji Bölümü ve Patoloji Bölümü'nde Doktora Sonrası Yan Dal Uzmanlığı (Postdoctoral Fellow, Akdamar Fellowship Programme) (2009-2011)
İstanbul Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Gastroenteroloji Kliniği'nde mecburi hizmet (2011-2014)
Marmara Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Gastroenteroloji Bilim Dalı'nda öğretim üyeliği (doçent ve profesörlük ünvanı) (2014-2023)
Bezmialem Vakıf Üniversitesi Dragos Hastanesi Gastroenteroloji Bölümü (2023-2024)
Tıbbi İlgi Alanları
Yemek Borusu ve Mide Hastalıkları (Reflü, Gastrit, Ülser, Helikobakter Pylori Enfeksiyonu)
Karaciğer Hastalıkları (Hepatit B, Hepatit C, Siroz)
Karaciğer Yağlanması
Ülseratif Kolit ve Crohn Hastalığı
İrritabl Barsak Sendromu (Huzursuz Barsak Sendromu)
Çölyak Hastalığı
Beslenme
Özellikli İşlem
Kapsül Endoskopi
Perkütan Endoskopik Gastrostomi
Mide Balonu
Fibroscan
Bilimsel Yayınlar
1: Bajaj JS, Choudhury AK, Xie Q, Kamath PS, Topazian M, Hayes PC, Torre A,
Desalegn H, Idilman R, Cao Z, Alvares-da-Silva MR, George J, Bush BJ, Thacker
LR, Wong F; CLEARED Investigators. Global disparities in mortality and liver
transplantation in hospitalised patients with cirrhosis: a prospective cohort
study for the CLEARED Consortium. Lancet Gastroenterol Hepatol. 2023
Jul;8(7):611-622. doi: 10.1016/S2468-1253(23)00098-5.
2: Demirtas CO, Gunduz F. Programmed Cell Death 1 and Hepatocellular Carcinoma:
An Epochal Story. J Gastrointest Cancer. 2021 Dec;52(4):1217-1222. doi: 10.1007/s12029-021-00758-z.
3: Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E,
Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Practicality and
potential restrictions of unresectable hepatocellular carcinoma prognostic
index. Hepatol Commun. 2022 Dec;6(12):3600-3601. doi: 10.1002/hep4.2093.
4: Demirtas CO, Gunduz F, Ozdogan OC. Surveillance Strategies for Hepatocellular
Carcinoma: Recent Advances and the Shifting Paradigm. J Gastrointest Cancer.
2021 Dec;52(4):1336-1339. doi: 10.1007/s12029-021-00755-2.
5: Alan AM, Alan O, Asadov R, Demirtas CO, Kani HT, Yumuk PF, Ozdogan OC,
Baltacioglu F, Gunduz F. Evaluation of the effectiveness of drug-eluting
transarterial chemoebolization in hepatocellular carcinoma. Hepatol Forum. 2023
May 18;4(2):53-60. doi: 10.14744/hf.2022.2022.0048.
6: Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E,
Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Proposal and Validation
of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability
Borders. Hepatol Commun. 2022 Mar;6(3):633-645. doi: 10.1002/hep4.1836.
7: Dane F, Seker M, Fulden Yumuk P, Gunduz F, Peker O, Basaran G, Serdar Turhal
N. Primary breast mantle cell lymphoma with atypical relapse patterns. J BUON.
2011 Jan-Mar;16(1):181-2.
8: Kani HT, Gündüz F. Should we use proton pump inhibitors as an add-on
treatment in hereditary hemochromatosis? Turk J Gastroenterol. 2018
Mar;29(2):254-255. doi: 10.5152/tjg.2018.17713.
9: Ergenc I, Gokcen P, Adali G, Tarik Kani H, Ozer Demirtas C, Gunduz F, Ataizi
Celikel C, Yilmaz Y. High incidence of hepatitis B core antibody positivity in
metabolic-associated fatty liver disease-related cirrhosis. Hepatol Forum. 2021
Jan 8;2(1):20-25. doi: 10.14744/hf.2020.2020.0025.
10: Akarca US, Unsal B, Sezgin O, Yalcin K, Akdogan M, Gonen C, Gunduz F,
Ozenirler S, Sonsuz A, Dincer D, Tekin SB, Yucel I, Akbulut H, Alkım C, Ozyilkan
O, Baygul A, Cevik ZM, Idilman R, Study Group OBOKR. Characteristics of Newly
Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective
Multicenter Observational 3K Registry Study. Turk J Gastroenterol. 2021
Dec;32(12):1019-1028. doi: 10.5152/tjg.2021.201171.
11: Direskeneli H, Tuna-Erdoğan E, Gündüz F, Bandurska-Luque A, Alparslan B,
Kebe M, Uyar FA, Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O,
Ozer HT, Akar S, Önen F, Seyahi E, Onat AM, Aydin SZ, Yilmaz N, Cefle A,
Cobankara V, Tunc E, Ozturk MA, Fresko I, Karaaslan Y, Akkoc N, Yücel AE, Kiraz
S, Keser G, Inanc M, Saruhan-Direskeneli G. PDCD1 polymorphisms are not
associated with Takayasu's arteritis in Turkey. Clin Exp Rheumatol. 2012 Jan-
Feb;30(1 Suppl 70):S11-4.
12: Bilgen A, Kani HT, Akdeniz E, Alahdab YO, Ozdogan O, Gunduz F. Effects of
vitamin D level on survival in patients with hepatocellular carcinoma. Hepatol
Forum. 2020 Sep 21;1(3):97-100. doi: 10.14744/hf.2020.2020.0017.
13: Demirtaş CO, Tolu T, Keklikkıran Ç, Özdoğan OC, Gündüz F. Hepatocellular
Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance:
A Single-Center Cohort Study. Turk J Gastroenterol. 2021 Aug;32(8):685-693. doi:
10.5152/tjg.2021.20677.
14: Gündüz F, Kani HT, Chang S, Akdeniz E, Eren F, Yılmaz Y, Alahdab YÖ. Effect
of carbon dioxide versus room air insufflation on post-colonoscopic pain: A
prospective, randomized, controlled study. Turk J Gastroenterol. 2020
Oct;31(10):676-680. doi: 10.5152/tjg.2020.20596.
15: Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman
DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External
validation of the Toronto hepatocellular carcinoma risk index in Turkish
cirrhotic patients. Eur J Gastroenterol Hepatol. 2020 Jul;32(7):882-888. doi:
10.1097/MEG.0000000000001685.
16: Değertekin B, Demir M, Akarca US, Kani HT, Üçbilek E, Yıldırım E, Güzelbulut
F, Balkan A, Vatansever S, Danış N, Demircan M, Soylu A, Yaras S, Kartal A,
Kefeli A, Gündüz F, Yalçın K, Erarslan E, Aladağ M, Harputluoğlu M, Özakyol A,
Temel T, Akarsu M, Sümer H, Akın M, Albayrak B, Sen İ, Alkım H, Uyanıkoğlu A,
Irak K, Öztaşkın S, Uğurlu ÇB, Güneş Ş, Gürel S, Nuriyev K, İnci İ, Kaçar S,
Dinçer D, Doğanay L, Göktürk HS, Mert A, Coşar AM, Dursun H, Atalay R, Akbulut
S, Balkan Y, Koklu H, Şimşek H, Özdoğan O, Çoban M. Real-world efficacy and
safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ±
Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Turk J Gastroenterol. 2020 Dec;31(12):883-893. doi: 10.5152/tjg.2020.20696.
17: Hazari S, Hefler HJ, Chandra PK, Poat B, Gunduz F, Ooms T, Wu T, Balart LA,
Dash S. Hepatocellular carcinoma xenograft supports HCV replication: a mouse
model for evaluating antivirals. World J Gastroenterol. 2011 Jan
21;17(3):300-12. doi: 10.3748/wjg.v17.i3.300.
18: Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab
YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly
effective in the surveillance of hepatocellular carcinoma among cirrhotic
patients. Eur J Gastroenterol Hepatol. 2020 Apr;32(4):517-523. doi:
10.1097/MEG.0000000000001528.
19: Ozdemir FT, Tiftikci A, Sancak S, Eren F, Tahan V, Akın H, Gündüz F, Kedrah
AE, Ustündağ Y, Avşar E, Tözün N, Ozdoğan O. The prevalence of the mutation in
codon 249 of the P53 gene in patients with hepatocellular carcinoma (HCC) in
Turkey. J Gastrointest Cancer. 2010 Sep;41(3):185-9. doi:
10.1007/s12029-010-9140-5.
20: Demirtas CO, Eren F, Yilmaz D, Ozdogan OC, Gunduz F. Does Genetic Variation
in PNPLA3, TM6SF2 and HSD17B13 have a Role in the Development or Prognosis of
Hepatocellular Carcinoma in Turkish Patients with Hepatitis B? J Gastrointestin
Liver Dis. 2024 Jun 29;33(2):203-211. doi: 10.15403/jgld-5474.
21: Gunduz F, Mallikarjun C, Balart LA, Dash S. Interferon alpha induced
intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV
infection. Exp Mol Pathol. 2014 Feb;96(1):36-41. doi:
10.1016/j.yexmp.2013.10.016.
22: Datta S, Hazari S, Chandra PK, Samara M, Poat B, Gunduz F, Wimley WC, Hauser
H, Koster M, Lamaze C, Balart LA, Garry RF, Dash S. Mechanism of HCV's
resistance to IFN-α in cell culture involves expression of functional IFN-α
receptor 1. Virol J. 2011 Jul 14;8:351. doi: 10.1186/1743-422X-8-351.
23: Kesen O, Kani HT, Yanartaş Ö, Aykut UE, Gök B, Gündüz F, Yılmaz Y, Özdoğan
OC, Özen Alahdab Y. Evaluation of depression, anxiety and quality of life in
hepatitis C patients who treated with direct acting antiviral agents. Turk J
Gastroenterol. 2019 Sep;30(9):801-806. doi: 10.5152/tjg.2019.18679.
24: Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu
Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven
H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S,
Akarca US; Early Access Program (EAP) Study Groupa. Low recurrence rate of
hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a
real-world chronic hepatitis C patients cohort. J Viral Hepat. 2019
Jun;26(6):666-674. doi: 10.1111/jvh.13075.
25: Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. Sertraline hepatotoxicity:
report of a case and review of the literature. Dig Dis Sci. 2009
Jul;54(7):1589-91. doi: 10.1007/s10620-008-0524-3.
26: Yeşil A, Gönen C, Senateş E, Paker N, Gökden Y, Koçhan K, Erdem ED, Gündüz
F. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels
and inflammatory bowel disease type and activity. Dig Dis Sci. 2013
Sep;58(9):2587-93. doi: 10.1007/s10620-013-2676-z.
27: Alahdab YO, Eren F, Giral A, Gunduz F, Kedrah AE, Atug O, Yilmaz Y, Kalayci
O, Kalayci C. Preliminary evidence of an association between the functional
c-kit rs6554199 polymorphism and achalasia in a Turkish population.
Neurogastroenterol Motil. 2012 Jan;24(1):27-30. doi:10.1111/j.1365-2982.2011.01793.x.
28: Demirci AF, Demirtas CO, Eren F, Yilmaz D, Keklikkiran C, Ozdogan OC, Gunduz
F. Evaluation of the Association between Programmed Cell Death-1 Gene
Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A
Pilot Study. J Gastrointestin Liver Dis. 2020 Oct 27;29(4):617-622. doi:
10.15403/jgld-2623.
29: Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, Bruce D, Cohen
AJ, Bohorquez HE, Carmody I, Loss G, Balart LA, Wu T, Dash S. Impaired
expression of type I and type II interferon receptors in HCV-associated chronic
liver disease and liver cirrhosis. PLoS One. 2014 Sep 29;9(9):e108616. doi:
10.1371/journal.pone.0108616.
30: Demirtas CÖ, Keklikkıran Ç, Mehdiyev S, Ergenç İ, Özen Alahdab Y, Gündüz F,
Yılmaz Y, Atuğ Ö, Özdoğan OC. Recommendations for Reopening Endoscopy Units in
Turkey: A Set-up Plan from a Tertiary Center in Istanbul. Turk J Gastroenterol.
2021 Feb;32(2):113-115. doi: 10.5152/tjg.2021.20434.
31: Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash
S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective
Jak-Stat signaling and inhibits HCV RNA replication. Virol J. 2010 Oct 12;7:265.
doi: 10.1186/1743-422X-7-265.
32: Poat B, Hazari S, Chandra PK, Gunduz F, Balart LA, Alvarez X, Dash S. SH2
modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α
resistant HCV replicon cells. PLoS One. 2010 Sep 30;5(9):e13117. doi:
10.1371/journal.pone.0013117.
33: Demirtas CO, Gunduz F. Letter: Is female sex an independent predictor of
favourable prognosis in hepatocellular carcinoma? Aliment Pharmacol Ther. 2020
Dec;52(11-12):1765-1766. doi: 10.1111/apt.16088.
34: Gunduz F, Aboulnasr FM, Chandra PK, Hazari S, Poat B, Baker DP, Balart LA,
Dash S. Free fatty acids induce ER stress and block antiviral activity of
interferon alpha against hepatitis C virus in cell culture. Virol J. 2012 Aug
3;9:143. doi: 10.1186/1743-422X-9-143.
35: Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi
M, Garry RF, Dash S. Intracytoplasmic stable expression of IgG1 antibody
targeting NS3 helicase inhibits replication of highly efficient hepatitis C
Virus 2a clone. Virol J. 2010 Jun 7;7:118. doi: 10.1186/1743-422X-7-118.
36: Sahin N, Gunduz F, Inanc N, Direskeneli H, Saruhan-Direskeneli G. No
association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey.
Rheumatol Int. 2009 Nov;30(1):81-3. doi: 10.1007/s00296-009-0919-2.
Üyelikler
Türk Karaciğer Araştırmaları Derneği (Viral Hepatit Çalışma Grubu Sekreterliği)
Türk Gastroenteroloji Derneği
İnflamatuvar Barsak Hastalıkları Derneği